Mutations in the gyrA, parC, and parE Genes Associated with Fluoroquinolone Resistance in Clinical Isolates of Mycoplasma hominis

AUTOR(ES)

Bebear, Cécile M.

FONTE

American Society for Microbiology

RESUMO

Five clinical isolates of Mycoplasma hominis from three different patients were examined for resistance to fluoroquinolones; some of these isolates were probably identical. All five isolates harbored amino acid substitutions in the quinolone resistance-determining regions of both DNA gyrase (GyrA) and topoisomerase IV (ParC or ParE). Furthermore, the novobiocin MIC for three isolates showed a significant increase. This is the first characterization of fluoroquinolone-resistant clinical mycoplasma isolates from humans.

Documentos Relacionados

• Fluoroquinolone Resistance Mutations in the parC, parE, and gyrA Genes of Clinical Isolates of Viridans Group Streptococci
• Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parE Loci
• Prevalence of Mutations within the Quinolone Resistance-Determining Region of gyrA, gyrB, parC, and parE and Association with Antibiotic Resistance in Quinolone-Resistant Salmonella enterica
• High-Level Resistance to Fluoroquinolones Linked to Mutations in gyrA, parC, and parE in Salmonella enterica Serovar Schwarzengrund Isolates from Humans in Taiwan
• Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa.